CD20 - CHO Recombinant Cell Line

SKU:BHC18200309
Research Validated
Overview
Click light‑blue chips for details
CD20 - CHO Recombinant Cell Line is a CAR-T Cell Line (CHO background, Human origin, BSL-1) from BPS Bioscience. Designed for useful as cd20-expressing target cells in co-culture assays with cd20-car-t cells for cd20-specific cell killing assays. workflows.
Parental Cell Line CHO
Species Human
Biosafety Level BSL-1
Product Type CAR-T Cell Line
Mycoplasma Tested Confirmed Negative
Storage Liquid Nitrogen
Options selector
Catalog no. Expression Level Size
79624-H High
79624-M Medium
Available Options

Select the variant that best fits your experiment. Availability and lead time may vary by option.

  • Options: Expression Level (2) — High, Medium; Size: 2 Vials
  • Lead time: options listed in "Availability Content"; other statuses may take longer.
  • Storage: Store in liquid nitrogen immediately upon receipt.
  • Shipping: cold-chain shipment (typically with ice packs).
  • Upon receipt: store at the recommended temperature as soon as possible.
  • Sales terms and conditions: Please review prior to ordering.
Field Specification
Mfr No 79624
Accession Number NM_152866
Alternative Names rituximab
Product Type
  • CAR-T Cell Line
Shipping -80°C (dry ice)
Species Human
Storage Store in liquid nitrogen immediately upon receipt.
UniProt # P11836

Scientific Background

CD20 (MS4A1) is a glycosylated phosphoprotein expressed on the cell surface of B cells. Although the functional significance of CD20 is not clear, and CD20 has no known ligands, CD20 has been shown to regulate intracellular calcium levels. CD20 is a highly attractive target antigen for immunotherapy because it is expressed on more than 90% of patients with B-cell lymphoma. First approved in 1997, Rituximab (Rituxan) is a chimeric monoclonal antibody targeting CD20 and has been classified by the World Health Organization as an “Essential Medicine”. Since then, additional monoclonal antibodies against CD20 have been approved or are being tested in clinical trials for the treatment of multiple sclerosis (MS), chronic lymphocytic leukemia (CLL), follicular lymphoma, diffuse large B cell lymphoma (DLBCL), rheumatoid arthritis, non-Hodgkin’s lymphoma, systemic lupus erythematosus, and myalgic encephalomyelitis (chronic fatigue syndrome). Additionally, more recently, anti-CD20-CD19 bispecific CAR-T cells have been developed to address concerns over potential relapse.

Product Description

CAR T-Cell Therapy

Recombinant clonal stable CHO cell line constitutively expressing full length human CD20 protein, also known as MS4A1 (Genbank #NM_152866). Surface expression of CD20 was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of CD20 expression (High, Medium) to mimic different stages of cancer target cells with various CD20 expression levels.

Product Specifications

Host Cell Line CHO
Host Species Hamster
Transfection Method Lipofectamine 2000
Supplied As Each vial contains ~ 2 x 10^6 cells in 1 ml of 10% DMSO in FBS.
Harmonized Tariff Code 3002-5900

Quality Control & Validation

✓ Mycoplasma-Tested

This cell line has been screened using the MycoAlert™ Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set (Lonza, #LT07-518) was used as a positive control.

Usage Notes

See data sheet for detailed culturing and assay protocol.

Safety & Handling

⚠ Avoid freeze/thaw cycles.

Regulatory Information

License RequiredYes
Living Modified OrganismYes

License Disclosure

LICENSE DISCLOSURE: Purchase of this cell line grants you with a 10-year license to use this cell line in your immediate laboratory, for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make the cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit the use of this cell line in humans or for therapeutic or drug use. The license does not permit modification of the cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license and result in an immediate cease of sales and distribution of BPS products to your laboratory. BPS does not warrant the suitability of the cell line for any particular use, and does not accept any liability in connection with the handling or use of the cell line. Modifications of this cell line, transfer to another facility, or commercial use of the cells may require a separate license and additional fees; contact sales@bpsbioscience.com for details. Publications using this cell line should reference BPS Bioscience, Inc., San Diego.

Related Products

Related Products: Cat. #79067, 79107, 79509

Required Accessories: Cat. #79539,60186,79796

What is the parental cell line for this product?

This product is engineered on a CHO background (Human origin). The CHO host was selected for its compatibility with stable transfection and the target pathway or assay type. Consult the product datasheet for passage number guidance and recommended culture media.

What biosafety level is required for this cell line?

This product is classified as BSL-1. Standard microbiological practices (gloves, lab coat, eye protection) are sufficient. No specialized containment facility is required beyond a clean bench. Consult your institutional IBC for GMO registration requirements.

Has this cell line been tested for mycoplasma contamination?

Yes. This cell line has been screened using the MycoAlert™ Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set (Lonza, #LT07-518) was used as a positive control. We recommend that you independently confirm mycoplasma-negative status after receipt and periodically during routine culture using a validated detection kit.

What are the recommended storage conditions?

Store this product at Liquid Nitrogen. Specifically: Store in liquid nitrogen immediately upon receipt. Transfer cells from dry-ice shipping to the recommended storage immediately upon receipt. Avoid repeated freeze-thaw cycles, which reduce viability and may alter expression characteristics.

Is a license required to use this product?

Yes, a license is required (Yes). Purchase of this cell line grants a time-limited research-use license for use in your immediate laboratory only. This license does not permit redistribution, sub-licensing, transfer to other institutions, or commercial use. Refer to the License Disclosure section on this page or contact BPS Bioscience for details regarding modifications or commercial licensing.

What method was used to generate this cell line?

This stable cell line was generated using Lipofectamine 2000 for transgene delivery into the parental host. The stably integrated cells were selected using the appropriate resistance marker and verified for expression prior to cryopreservation.

Can't find the cell line you need—or require a custom engineered model for your study? We offer end-to-end support for diverse research needs, including:

  • Cell line sourcing and selection (species, tissue, and disease model matching)
  • Stable cell line engineering (overexpression, knockdown, knockout via CRISPR/Cas9, shRNA, sgRNA)
  • Reporter gene integration (GFP, RFP, luciferase, fluorescent/bioluminescent constructs)
  • Genome editing and knockin (point mutations, tagged endogenous proteins, conditional alleles)
  • Inducible expression systems (Tet-On/Off and regulatable constructs)
  • Drug resistance marker selection (puromycin, G418, hygromycin, and others)
  • Custom growth and media optimisation for specific assay requirements
  • Scale-up production for high-throughput screening campaigns
  • Authentication and QC services (STR profiling, mycoplasma testing, viability assessment)

Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.

  1. Kosmas, C, et al. Anti-CD20-based therapy of B cell lymphoma: state of the art. Leukemia. 2002; 16: 2004-2015 2. Cragg, MS, et al. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 2005; 8: 140-174 3. Martyniszyn, A, et al. CD20-CD19 bispecific CAR T cells for the treatment of B cell malignancies. Hum Gene Ther. 2017 Dec; 28(12): 1147-1157 4. Lee, SY, et al. Preclinical optimization of a CD20-specific chimeric antigen receptor vector and culture conditions. J Immunother. 2018 Jan; 41(1): 19-31
Matches this product
15%OFF
15% Off Cancer Antibodies
Ends Sep 30 ONCO15
Matches this product
10% OFF
10% OFF CELL LINES-Limited-Time Offer
Ends Sep 30 CELL10
$50 OFF
$50 Off All ELISA Kits
Limited time ELISA50
FREE SAMPLE
Free Sample – CellTrypase Recombinant Trypsin-Like Enzyme
Limited time offer – availa... FREESAMPLE
FREE SAMPLE
Free Sample – MycoFold™ Growth Factors
Limited time offer – availa... Request Free Sample

Get a Quote

Please use this form for bulk quantity requests or customized products.

Contact Information

Product Information

Try Celltrypse Free – Request Your Sample Today

Experience the power of Celltrypse™, c-LEcta's innovative enzyme solution for gentle and efficient cell dissociation. Request your free sample and discover a superior alternative for your cell culture workflows.

Try Celltrypse Free – Request Your Sample Today

Try Celltrypse Free – Request Your Sample Today

Experience the power of Celltrypse™, c-LEcta's innovative enzyme solution for gentle and efficient cell dissociation. Request your free sample and discover a superior alternative for your cell culture workflows.

Try Celltrypse Free – Request Your Sample Today